The litigation centers on allegations that Regeneron and its executives misled shareholders regarding the company's business practices. The scrutiny intensified on April 29, 2026, when the firm altered its Phase III Fianlimab-Libtayo study, triggering a 6.21% decline in share price. Investor confidence suffered a sharper blow on May 15, 2026, when the company confirmed the trial failed to reach statistical significance for its primary progression-free survival endpoint, causing the stock to tumble an additional 9.82% to close at $629.68.
Pomerantz LLP is spearheading the case, representing those who acquired securities during the designated class period. Shareholders interested in serving as a lead plaintiff must file their request with the court by September 14, 2026. Interested parties are directed to contact Danielle Peyton at dpeyton@pomlaw.com or by calling 646-581-9980 to review their eligibility and submission requirements.
Comments (0)
No comments yet. Be the first!